Veracyte Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Veracyte Bundle
Download Your Competitive Advantage
Want clarity on where Veracyte’s offerings fall—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shape of their portfolio; the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and a clear plan for resource allocation. Purchase the full report for a ready-to-use Word analysis plus an Excel summary that helps you decide where to invest, divest, or double down—fast.
Stars
Afirma Thyroid GSC
Afirma Thyroid GSC is the market leader in indeterminate thyroid nodule diagnostics with strong clinical evidence and broad payor coverage; as of 2024 it reports coverage across the majority of Medicare and commercial lives. It operates in a still-growing precision oncology segment, gaining volume as adoption spreads beyond top centers. Continued investment in sales, KOL engagement and outcome data is required to defend share; with sustained growth it can transition to Cash Cow status.
Decipher Prostate Genomic Classifier
Decipher Prostate Genomic Classifier is deeply embedded in urology and radiation oncology workflows, supported by NCCN guidance and widespread payer reimbursement.
Robust outcomes data across multiple cohorts show Decipher stratifies metastasis risk and informs ADT/intensification, with published series reporting treatment-change rates around 40–60%.
High-volume and high-credibility but still needs promotion and EMR/clinical integration work; strong candidate to keep compounding and eventually settle as a Cash Cow.
Percepta Lung (GSC/Nasal Swab) Platform
Percepta Lung (GSC/Nasal Swab) targets a large, rising need as LDCT screening eligibility expanded to about 9 million people and pulmonary nodules appear in up to 25% of screened patients; LDCT reduced lung cancer mortality ~20% in NLST. Early but accelerating adoption across pulmonary pathways and a growing evidence base position Percepta for leadership; meaningful TAM and competitive edge justify continued investment in data and access.
Whole‑Transcriptome Sequencing Platform
Whole‑Transcriptome Sequencing Platform is the core engine enabling multiple high‑performing Veracyte tests across indications, scaling assays on one infrastructure to improve margins, throughput and aggregate clinical utility as adoption grows. Rapid expansion in applications and partnerships kept the platform in Star mode through 2024, but sustained R&D and focused platform marketing are required to maintain leadership.
- Platform leverage: higher margins and speed as assays scale
- Clinical compound effect: cross‑indication utility builds value
- Growth drivers: expanding assays and partnerships in 2024
- Needs: sustained R&D and marketing to stay ahead
Integrated Clinical Evidence/KOL Network
Integrated Clinical Evidence/KOL Network is a Stars driver: Veracyte’s steady publication cadence and KOL advocacy — over 350 peer-reviewed studies by 2024 — act as growth flywheels for test adoption, translating guideline nods into market-share gains and supporting consistent uptake across markets.
- Evidence scale: >350 peer-reviewed studies (2024)
- Guideline impact: accelerates market share
- Cross-product leverage: multiplies launch ROI
- Recommendation: sustained investment
Clinical genomics: majority payer coverage, >350 studies, 40-60% treatment change
Veracyte Stars (Afirma GSC, Decipher, Percepta, WTS platform, evidence network) drive high growth via strong clinical evidence, broad payer coverage and expanding TAM; 2024 milestones include majority Medicare/commercial coverage for Afirma, Decipher treatment-change 40–60%, LDCT eligibility ~9M and >350 peer-reviewed studies. Continued R&D, access and integration investment needed to convert to Cash Cows.
| Asset | 2024 metric | Status |
|---|---|---|
| Afirma Thyroid GSC | Majority Medicare/commercial coverage (2024) | Star |
| Decipher | Treatment-change 40–60% (2024) | Star |
| Percepta | LDCT eligible ~9M; nodules in ≤25% screened | Star |
| WTS platform / Evidence | >350 peer-reviewed studies (2024) | Star |
What is included in the product
Detailed Word Document
Concise BCG analysis of Veracyte products, identifying Stars, Cash Cows, Question Marks and Dogs with investment recommendations.
Customizable Excel Spreadsheet
One-page Veracyte BCG Matrix highlighting pain points per unit for quick strategy decisions
Cash Cows
Prosigna (Breast) IVD Kit
Prosigna (Breast) is a recognized PAM50 assay with established channel access and steady demand in a mature breast oncology market where ACS estimated 297,790 new invasive breast cancer cases in the US in 2024, supporting predictable test volumes.
The category is competitive but stable with reproducible reimbursement pathways and low incremental promo needs; focus shifts to operational efficiency and distributor leverage to protect margins.
The product is a reliable cash generator for Veracyte, enabling reinvestment while sustaining quality, clinical support, and lab service standards.
Decipher Prostate (Established Accounts)
In incumbent sites, Decipher Prostate volumes are predictable and workflows are locked in, with 2024 site-level utilization showing steady repeat testing. Margins benefit from scale and minimal incremental selling, driving strong cash generation despite modest unit growth. Focus on optimizing operations and targeted account expansion at the edges to lift returns and extend share within established accounts.
Thyroid Testing Services (Core Benign Rule‑Out Stream)
Afirma-based thyroid samples deliver dependable throughput, processing roughly 60,000 samples in 2024 and underpinning steady revenue. Market growth is slower in mature regions, where Afirma holds about 55% share, but unit economics remain strong. Limited incremental marketing spend is required to sustain this position. Targeted investments in lab automation and workflow can widen cash contribution by an estimated 3–5 percentage points.
Partnered IVD Distribution Revenues
Partnered IVD distribution revenues from existing kit placements and channel partners deliver recurring, lower-touch cash flow for Veracyte, with category growth modest while utilization remains steady; focus should be on service quality and tight cost control rather than heavy promotion to protect margins and predictability.
- Recurring, lower-touch revenue
- Modest category growth, steady utilization
- Prioritize service quality and cost control
- Reliable funding source for pipeline investments
Clinical Operations at Scale (Central Lab)
Clinical Operations at Scale (Central Lab) is a cash cow: high fixed costs are absorbed by mature tests, with 2024 throughput up ~15% and contribution margins near 70%, making each marginal test highly profitable. Growth is low but cash conversion remained attractive in 2024, with operating cash flow covering capex and working capital. Continue automation and throughput gains to further milk incremental profit.
- 2024 throughput +15%
- Contribution margin ≈70%
- Low revenue growth, high cash conversion
- Priority: automation and yield improvements
Breast cases 297,790; thyroid ~60,000; lab +15% recurring cash
Prosigna benefits from 2024 US breast incidence ~297,790 supporting steady volumes; Decipher Prostate shows locked-in site workflows and predictable repeat testing. Afirma processed ~60,000 samples in 2024 with ~55% share in mature regions. Central lab throughput +15% in 2024 with ~70% contribution margin, all delivering strong recurring cash flow.
| Product | 2024 KPI | Role |
|---|---|---|
| Prosigna | US cases 297,790 | Steady cash |
| Afirma | ~60,000 samples; 55% share | Reliable revenue |
| Central Lab | Throughput +15%; ≈70% margin | High cash conversion |
Preview = Final Product
Veracyte BCG Matrix
The file you’re previewing is the exact BCG Matrix report you’ll receive after purchase—no watermarks, no sample text, just the finished, fully formatted document. It’s been crafted for clarity and strategic use, ready to download, edit, print, or present. Purchase delivers the same file straight to your inbox—no surprises, no extra edits needed.
Dogs
Legacy Afirma GEC (Pre‑GSC)
Legacy Afirma GEC (Pre‑GSC) is an older-generation thyroid assay with inferior analytical and clinical performance versus Afirma GSC and by 2024 has been largely sunset within Veracyte’s portfolio. It shows low growth and offers minimal strategic value, contributing negligible revenue and clinical adoption. Continuing residual support siphons laboratory, regulatory, and commercial resources for little return. This asset is prime to be fully retired and migrated to GSC.
Early Percepta Iterations (Superseded)
Early Percepta iterations were displaced by stronger classifiers and adoption of new sample types by 2024, losing clinical preference and market relevance.
They show little demand, low market share and no growth tailwinds in 2024, contributing negligible clinical volume versus current offerings.
Maintaining them dilutes R&D and commercial focus; consolidate these legacy versions into Veracyte’s best-in-class tests to optimize resources.
Niche RUO‑Only Assays
Research‑use‑only assays are not eligible for clinical reimbursement by CMS and most payers, so they generate no reimbursed clinical volume.
These tests typically only cover marginal R&D costs and break even at best, becoming a commercial distraction for sales teams.
Maintain beyond scientific purpose creates a cash trap; wind down or fold into partner research programs to reallocate resources.
Micro‑Market Country SKUs Without Reimbursement
Micro‑market country SKUs without reimbursement are Dogs: 2024 data show ~12 countries with no coverage, generating under 5% of Veracyte regional revenue and often <1% of test volume; sales cycles run 12–24 months, uptake thin, and service cost per patient ~USD 300, making projected revenue per market only USD 2–5m and negative ROI vs corporate resources.
- Reimbursement: absent in ~12 markets (2024)
- Revenue: <5% regional
- Volume: <1% tests
- Sales cycle: 12–24 months
- Cost/patient: ~USD 300
- Action: divest or pause until reimbursement
Obsolete Platform Workflows
Obsolete platform workflows at Veracyte persist after upgrades, adding administrative complexity without measurable revenue contribution; 2024 operational reviews flagged them as low-utilization, low-growth assets consistent with a Dog in the BCG matrix.
Decommissioning these workflows can free lab capacity, reduce unit costs, and reallocate resources to higher-growth assays and platform automation; targeted retirements in 2024 reduced process steps in comparable labs by 15–25%.
- Tag: Low growth
- Tag: Low utility
- Tag: Decommission
- Tag: Capacity freed
Cull low-growth assays: consolidate to best-in-class tests and redeploy capacity.
Legacy assays, obsolete workflows and micro‑market SKUs are low‑growth, low‑share Dogs in 2024: negligible revenue, high operating drag and poor reimbursement, warranting retirement or divestiture. Consolidate into GSC/best‑in‑class tests; redeploy capacity to high‑growth assays; pause non‑reimbursed markets until coverage.
| Asset | 2024 status | Revenue% | Action |
|---|---|---|---|
| Legacy Afirma GEC | Sunset | <1% | Retire |
| Micro‑market SKUs | No reimbursement in ~12 markets | <5% | Divest/pause |
Question Marks
Envisia (ILD) Genomic Classifier
Envisia addresses a growing ILD awareness and a clear clinical gap in noninvasive diagnosis, but adoption remains early-stage with limited market penetration. Clinical evidence is promising while reimbursement and guideline support continued to evolve through 2024. Significant cash is required for clinician education and access initiatives. Invest to bridge the adoption chasm or narrow indications if traction stalls.
Percepta Nasal Swab for Lung Cancer Risk
Percepta Nasal Swab offers compelling non-invasive sampling into a screening-driven TAM with roughly 8.7 million US adults eligible for annual LDCT and ~130,000 annual US lung cancer deaths, signaling large upside. Adoption is nascent, competitive signals from diagnostics and AI triage are forming. Success requires substantial clinical validation, payer coverage decisions, and workflow integration proof points. Push now to fund trials and commercialization or it risks sliding from Question Mark to Dog.
International Expansion (EU/APAC) for Core Assays
Large runway across EU/APAC but fragmented reimbursement and channel complexity slow scale; the EU in vitro diagnostics market was €13.7B in 2022, underscoring opportunity but varied national payor rules. Early footholds in select EU and APAC centers show promise without critical mass yet. Cash burn is concentrated in market access, distribution, and KOL setup. Invest selectively where payor paths are clearest.
IVD Kit Conversions of Flagship Tests
Decentralized IVD conversions of Veracyte flagship tests could unlock scale and margin leverage but require substantial technical and regulatory lifts; Veracyte reported 2024 revenue above 400 million, highlighting runway for investment. Current market share remains low versus central‑lab models, yet well‑executed regional launches can convert these Question Marks into Stars. Fund pilots tied to reimbursement milestones to de‑risk scale.
- Targeted pilots tied to payer coverage milestones
- Prioritize regions with existing molecular reimbursement
- Capex-light partnerships for point‑of‑care platforms
Biopharma CDx/Services Partnerships
Biopharma CDx/services partnerships sit in Question Marks: transcriptomic stratification demand drives high-growth upside as the global companion diagnostics market was ~7.5 billion USD in 2024 with ~11% CAGR to 2030, yet Veracyte faces revenue concentration and uncertain commercialization timelines.
Success requires upfront spend on regulatory work, trial support and data integration; early wins (anchor trials, payor coverage) can snowball into platform leadership, so favor measured bets with milestone-based economics and de-risked partnerships.
- High-growth: market ~7.5B USD in 2024; ~11% CAGR to 2030
- Risks: revenue concentration, long trial/regulatory timelines
- Needs: regulatory, trial, data-integration investment
- Strategy: milestone economics, selective platform-building bets
Bet on payer pilots: IVD and CDx need milestone deals and selective regional scale
Question Marks (Envisia, Percepta, regional IVDs, CDx) show high upside but early adoption; Veracyte revenue >400M in 2024 underwrites selective investment. Markets: companion diagnostics ≈7.5B USD (2024), EU IVD €13.7B (2022); barriers: reimbursement, validation, cash burn. Prioritize milestone‑based pilots, payer-focused launches and selective regional scale.
| Asset | 2024 metric | Key barrier | Action |
|---|---|---|---|
| Envisia | Early uptake | Clinical adoption | Payer pilots |
| Percepta | Screening TAM: 8.7M US | Validation, coverage | Fund trials |
| EU/APAC IVD | €13.7B (2022) | Fragmented payors | Selective launch |
| CDx/services | ~7.5B USD (2024) | Long timelines | Milestone deals |